search
Back to results

Multicenter Study to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Single Tooth Restorations

Primary Purpose

Jaw, Edentulous, Partially

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
PrimeTaper EV implant
Sponsored by
Dentsply Sirona Implants and Consumables
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Jaw, Edentulous, Partially

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult aged 18-75 years.
  • Willing and able to sign and date the informed consent form.
  • In need of an implant in position 16 to 26 or 36 to 46, and each subject can only receive one implant.
  • Deemed by the investigator as likely to present with an initially stable implant situation.
  • A stable occlusion, i.e. an opposing natural dentition, a crown, an implant-supported fixed or removable prosthesis, a partial removable prosthesis or a full denture.
  • An adjacent tooth (root with natural or artificial crown) or an implant-supported crown mesially and distally. Exemption: If the planned implant is in the first molar position, an edentulous space is accepted distally

Exclusion Criteria:

  • Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.
  • Unlikely to be able to comply with clinical investigation procedures according to investigator's judgement.
  • Unable or unwilling to return for follow-up visits for a period of 5 years.
  • Known allergy or hypersensitivity to titanium and/or stainless steel.
  • Uncontrolled pathological process in the oral cavity, e.g. untreated rampant caries and uncontrolled periodontal disease.
  • Uncontrolled para-functional habits, e.g. bruxism.
  • Current need of any Guided Bone Regeneration (GBR) procedure in the planned implant area (gap filling at immediate placement and soft tissue grafting are allowed).
  • Systemic or local disease or condition that would compromise post-operative healing and/ or osseointegration.
  • Immunosuppression, use of corticosteroids, per-os or intravenous bisphosphonate use, or any other medication such as anti-resorptive therapy or monoclonal antibodies that could compromise post-operative healing and/or osseointegration.
  • Any other condition that would make the subject unsuitable for participation, including but not limited to;

    • History of radiation therapy in the head and neck region.
    • History of chemotherapy within 5 years prior to surgery.
    • Present alcohol and/or drug abuse.
    • Ongoing psychiatric illness.
    • Current smoking/use of tobacco, including e-cigarettes.
  • Any ongoing disease that would make the subject unsuitable for participation, including but not limited to;

    • Recent myocardial infarction (< 3 months*).
    • Recent cerebrovascular accident (< 3 months*).
    • Recent cardiac-valvular prosthesis placement (< 3 months*).
    • Hemorrhagic diathesis.
    • Severe liver dysfunction.
    • Known or suspected current malignancy.
    • Uncontrolled diabetes mellitus.
    • Florid infection.
  • Pregnant or breastfeeding females. (Pregnancy tests will be performed as per local requirements).
  • Previous enrolment in the present clinical investigation.
  • Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona staff and the clinical investigation site).
  • Simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last 6 months that may interfere with the present clinical investigation.

    • < 3 months is a strict exclusion criterion. After 3 month it is up to the investigator to judge whether the subject is considered suitable for participation or not.

Sites / Locations

  • University of Iowa
  • Catholic University of Leuven
  • Dental practice Dr Mischa Krebs
  • Studio Toia
  • Dr.F.L.Guljé, De Mondhoek

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single tooth restorations

Arm Description

A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.

Outcomes

Primary Outcome Measures

Implant survival, i.e. number of implants in place counted clinically, 1 year after permanent restoration.
Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

Secondary Outcome Measures

Implant survival, i.e. number of implants in place counted clinically, 2, 3, 4 and 5 years after permanent restoration.
Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.
Change of implant stability quotient value (ISQ) between implant placement and permanent restoration.
Implant stability will be evaluated through ISQ value using Resonance Frequency Analysis (RFA). The stability is presented as an ISQ value. The higher the ISQ value the higher the stability. Recorded as a numeric value (1-100).
Maximum insertion torque value for each implant at implant placement.
Maximum insertion torque value (ITV), based on ITV curve, measured in Ncm.
Final insertion torque value for each implant at implant placement.
Final insertion torque value (ITV), based on ITV curve, measured in Ncm.
Investigator questionnaire for each investigational medical device after implant placement.
Numerical scale 1-10, where 1 = totally disagree with the statement, and 10 = totally agree with the statement. Statements to be evaluated by the surgeon: "The implant was guided into the prepared osteotomy", "The implant followed the prepared osteotomy", "The implant has a good primary stability", "The drilling protocol is easy to use", "The implant has efficient cutting properties". Each statement will be evaluated separately.
Implant success, i.e., number of implants documented as successful at 1, 2, 3 and 5 years after permanent restoration.
Successful implants counted, i.e. 'Yes' or 'No'. An implant will be considered successful if all of the following criteria are fulfilled: Implant in place. Lack of evidence of peri-implant radiolucency in X-ray. Less than 1mm vertical bone loss during first year after loading with permanent restoration and 0,2mm annually thereafter. Absence of persistent and/or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or violation of the mandibular canal.
Change of marginal bone level up to 5 years post permanent restoration compared to permanent restoration.
MBL changes determined from radiographs, expressed as the distance from the implant reference point to the most coronal bone-to-implant contact on the mesial and distal side of the implant. The average will be calculated and compared for each evaluation period.
Change of probing pocket depth (PPD) in mm between permanent restoration, and 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.
Probing Pocket Depth (PPD) measured as the distance from the mucosal margin to the bottom of the probe-able pocket in mm.
Presence of bleeding on probing (BoP), at permanent restoration, and 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.
Bleeding on Probing (BoP) recorded as presence or absence of bleeding when probing to the bottom of the pocket.
Presence of plaque at 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.
Plaque recorded as presence or absence of plaque by visual inspection on four surfaces at each implant site.
Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies during the clinical investigation.
Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.

Full Information

First Posted
March 16, 2022
Last Updated
August 16, 2023
Sponsor
Dentsply Sirona Implants and Consumables
search

1. Study Identification

Unique Protocol Identification Number
NCT05315414
Brief Title
Multicenter Study to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Single Tooth Restorations
Official Title
An Open, Prospective, Multicenter Investigation to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Extraction Sockets and Healed Ridges - A 5 Year Follow-up
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 3, 2022 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dentsply Sirona Implants and Consumables

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the clinical outcome of implant survival of the PrimeTaper EV implant in single tooth restorations 1 year after permanent restoration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Jaw, Edentulous, Partially

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single tooth restorations
Arm Type
Experimental
Arm Description
A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.
Intervention Type
Device
Intervention Name(s)
PrimeTaper EV implant
Intervention Description
Tapered dental implant developed by Dentsply Sirona
Primary Outcome Measure Information:
Title
Implant survival, i.e. number of implants in place counted clinically, 1 year after permanent restoration.
Description
Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.
Time Frame
One year post permanent restoration (anticipated average 3 months after implant placement).
Secondary Outcome Measure Information:
Title
Implant survival, i.e. number of implants in place counted clinically, 2, 3, 4 and 5 years after permanent restoration.
Description
Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.
Time Frame
2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Title
Change of implant stability quotient value (ISQ) between implant placement and permanent restoration.
Description
Implant stability will be evaluated through ISQ value using Resonance Frequency Analysis (RFA). The stability is presented as an ISQ value. The higher the ISQ value the higher the stability. Recorded as a numeric value (1-100).
Time Frame
From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).
Title
Maximum insertion torque value for each implant at implant placement.
Description
Maximum insertion torque value (ITV), based on ITV curve, measured in Ncm.
Time Frame
At date of implant placement (anticipated average 1 month after inclusion).
Title
Final insertion torque value for each implant at implant placement.
Description
Final insertion torque value (ITV), based on ITV curve, measured in Ncm.
Time Frame
At date of implant placement (anticipated average 1 month after inclusion).
Title
Investigator questionnaire for each investigational medical device after implant placement.
Description
Numerical scale 1-10, where 1 = totally disagree with the statement, and 10 = totally agree with the statement. Statements to be evaluated by the surgeon: "The implant was guided into the prepared osteotomy", "The implant followed the prepared osteotomy", "The implant has a good primary stability", "The drilling protocol is easy to use", "The implant has efficient cutting properties". Each statement will be evaluated separately.
Time Frame
Immediately after implant placement (anticipated average 1 month after inclusion).
Title
Implant success, i.e., number of implants documented as successful at 1, 2, 3 and 5 years after permanent restoration.
Description
Successful implants counted, i.e. 'Yes' or 'No'. An implant will be considered successful if all of the following criteria are fulfilled: Implant in place. Lack of evidence of peri-implant radiolucency in X-ray. Less than 1mm vertical bone loss during first year after loading with permanent restoration and 0,2mm annually thereafter. Absence of persistent and/or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or violation of the mandibular canal.
Time Frame
1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Title
Change of marginal bone level up to 5 years post permanent restoration compared to permanent restoration.
Description
MBL changes determined from radiographs, expressed as the distance from the implant reference point to the most coronal bone-to-implant contact on the mesial and distal side of the implant. The average will be calculated and compared for each evaluation period.
Time Frame
At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.
Title
Change of probing pocket depth (PPD) in mm between permanent restoration, and 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.
Description
Probing Pocket Depth (PPD) measured as the distance from the mucosal margin to the bottom of the probe-able pocket in mm.
Time Frame
At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Title
Presence of bleeding on probing (BoP), at permanent restoration, and 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.
Description
Bleeding on Probing (BoP) recorded as presence or absence of bleeding when probing to the bottom of the pocket.
Time Frame
At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Title
Presence of plaque at 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.
Description
Plaque recorded as presence or absence of plaque by visual inspection on four surfaces at each implant site.
Time Frame
6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Title
Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies during the clinical investigation.
Description
Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.
Time Frame
Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult aged 18-75 years. Willing and able to sign and date the informed consent form. In need of an implant in position 16 to 26 or 36 to 46, and each subject can only receive one implant. Deemed by the investigator as likely to present with an initially stable implant situation. A stable occlusion, i.e. an opposing natural dentition, a crown, an implant-supported fixed or removable prosthesis, a partial removable prosthesis or a full denture. An adjacent tooth (root with natural or artificial crown) or an implant-supported crown mesially and distally. Exemption: If the planned implant is in the first molar position, an edentulous space is accepted distally Exclusion Criteria: Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation. Unlikely to be able to comply with clinical investigation procedures according to investigator's judgement. Unable or unwilling to return for follow-up visits for a period of 5 years. Known allergy or hypersensitivity to titanium and/or stainless steel. Uncontrolled pathological process in the oral cavity, e.g. untreated rampant caries and uncontrolled periodontal disease. Uncontrolled para-functional habits, e.g. bruxism. Current need of any Guided Bone Regeneration (GBR) procedure in the planned implant area (gap filling at immediate placement and soft tissue grafting are allowed). Systemic or local disease or condition that would compromise post-operative healing and/ or osseointegration. Immunosuppression, use of corticosteroids, per-os or intravenous bisphosphonate use, or any other medication such as anti-resorptive therapy or monoclonal antibodies that could compromise post-operative healing and/or osseointegration. Any other condition that would make the subject unsuitable for participation, including but not limited to; History of radiation therapy in the head and neck region. History of chemotherapy within 5 years prior to surgery. Present alcohol and/or drug abuse. Ongoing psychiatric illness. Current smoking/use of tobacco, including e-cigarettes. Any ongoing disease that would make the subject unsuitable for participation, including but not limited to; Recent myocardial infarction (< 3 months*). Recent cerebrovascular accident (< 3 months*). Recent cardiac-valvular prosthesis placement (< 3 months*). Hemorrhagic diathesis. Severe liver dysfunction. Known or suspected current malignancy. Uncontrolled diabetes mellitus. Florid infection. Pregnant or breastfeeding females. (Pregnancy tests will be performed as per local requirements). Previous enrolment in the present clinical investigation. Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona staff and the clinical investigation site). Simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last 6 months that may interfere with the present clinical investigation. < 3 months is a strict exclusion criterion. After 3 month it is up to the investigator to judge whether the subject is considered suitable for participation or not.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andy Temmerman, Prof.
Organizational Affiliation
KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242-1010
Country
United States
Facility Name
Catholic University of Leuven
City
Leuven
ZIP/Postal Code
B-3000
Country
Belgium
Facility Name
Dental practice Dr Mischa Krebs
City
Alzey
ZIP/Postal Code
DE-55232
Country
Germany
Facility Name
Studio Toia
City
Busto Arsizio
ZIP/Postal Code
IT-21052
Country
Italy
Facility Name
Dr.F.L.Guljé, De Mondhoek
City
Apeldoorn
ZIP/Postal Code
7315CA
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Multicenter Study to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Single Tooth Restorations

We'll reach out to this number within 24 hrs